Open Access

The persisting puzzle of racial disparity in triple negative breast cancer: looking through a new lens

Chakravarthy Garlapati1,Shriya Joshi1,Bikram Sahoo1,Shobhna Kapoor2,Ritu Aneja1,*
Department of Biology, Georgia State University, Atlanta, GA, USA
Department of Chemistry, Indian Institute of Technology Bombay, Powai, India
DOI: 10.2741/S527 Volume 11 Issue 1, pp.75-88
Published: 01 March 2019
*Corresponding Author(s):  
Ritu Aneja

Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen and progesterone receptors and absence of amplification of human epidermal growth factor receptor (HER2). This disease has no approved treatment with a poor prognosis particularly in African-American (AA) as compared to European-American (EA) patients. Gene ontology analysis showed specific gene pathways that are differentially regulated and gene signatures that are differentially expressed in AA as compared to EA. Such differences might underlie the basis for the aggressive nature and poor prognosis of TNBC in AA patients. In-depth studies of these pathways and differential genetic signature might give significant clues to improve our understanding of tumor biology associated with AA TNBC to advance the prognosis and survival rates. Along with gene ontology analysis, we suggest that post-translational modifications (PTM) could also play a crucial role in the dismal survival rate of AA TNBC patients. Further investigations are necessary to explore this terrain of PTMs to identify the racially disparate burden in TNBC.

Key words

Triple Negative Breast Cancer, Post Translational Modification, Racial Disparity, Gene Expression, Pathways, Review

2. Introduction

Triple-negative breast cancer (TNBC), a subtype of breast cancer (BC), accounts for 15-20% of all BC diagnoses in the US. It has been recognized that women of African descent are twice as likely to develop TNBC than women of European descent (1). As the name foretells, TNBCs lack estrogen, progesterone, and human epidermal growth factor receptors. Unfortunately, TNBCs are defined by what they “lack” rather than what they “have” and thus this negative nomenclature provides no actionable information on “druggable” targets. Aptly, this particular BC subtype has no FDA-approved targeted therapies thus far, and the survival rate is dismal (2-5).

Primarily, TNBC patients exhibit higher resistance to chemotherapy than hormone receptor (HR) positive BCs (6). TNBC patients, whose tumors metastasize to visceral organs, survive only for a year. Thus, diagnosis of metastatic TNBC is necessarily a death sentence for patients (6). The heterogeneous tumor biology, aggressive clinical course, and higher metastatic potential underscore an unmet need to understand the molecular pathways and signaling circuitries that could be targeted in TNBC to develop effective novel molecules to ultimately improve its prognosis (7) (Figure 1). Literature reports several targeted molecular therapies for TNBC that have shown promising results. These novel agents include small molecule inhibitors that specifically target poly-ADP-ribose-polymerase (PARP-1) (8, 9), epidermal growth factor receptor (EGFR) (10, 11), multi-tyrosine kinases (12, 13), as well as anti-angiogenic agents (14, 15). A study by Sparano JA et al., pointed out a distinct molecular signature; ~70% of genes related to kinase activity, cell division, proliferation, DNA repair, anti-apoptosis, and transcriptional regulation are differentially expressed in TNBC vs. non-TNBC subtype (16). This review focuses on racially-distinct differential gene expression signatures in TNBC and how these distinct features may provide insights into the mechanistic basis for aggressive TNBC and offer cues about druggable target space in racially diverse TNBC patients. More importantly, we offer a new perspective to look at racial disparities through the lens of post-translational modifications of key molecules.

Figure 1. Variety of critical aspects attributed to TNBC aggressiveness.

3. Dissecting the TNBC racially disparate burden

3.1. Does race influence TNBC onset and progression?

TNBC in AA women present higher mortality rates compared to women of European descent. The major contributing factors for such disparity are barriers to early screening, advanced disease stage at diagnosis, socio-demographic factors, socio-economic status, and lack of access to the healthcare treatment (17). AA premenopausal women exhibit a higher incidence and mortality rate compared to EA counterparts. However, postmenopausal women, do not show such a racial disparity (4, 18), suggesting that TNBC is significantly associated with younger age women of African descent (5).

Differences in survival outcomes among racially diverse TNBC patients remains controversial. Studies led by various groups such as Lund et al., (19) Bauer et al., (5) Carey et al., (20) and Sachdev et al., (21) have reported worse survival outcomes for women of African origin, after adjusting for socioeconomic factors, treatment delay, and tumor characteristics. Sachdev et al., showed that both unadjusted and stage-adjusted survival outcomes were better in EA over AA TNBC patients (21). On the other hand, other groups like Dawood et al., (22) O’ Brien et al., (23) and Sparano et al., (24) found no significant difference in survival outcomes between racially-distinct TNBC patients (4). Underlying these inconsistent results could be the nonuniformity of the biomarkers tested, lack of certainty of pathological parameters, lack of availability of treatment information to deduce the survival outcomes, and failure to consider multiple factors such as stage, grade, poverty index, and other treatment related factors (19).

Recently, Ademuyiwa et al., reported a detailed mutational analysis of AA and EA TNBC patients comparing the mutational landscape between the racially-distinct patient populations. Interestingly, they found no compelling differences in the panorama of mutated genes between AA and EA TNBC patients. Also, they found no racial differences between AA and EA TNBC patients in high prevalence genes (TP53, PI3CA, MLL3), attributed to the fact that there is no significant difference in somatic mutations of these genes (25). Collectively, these findings suggest that the aggressive disease course seen among AA TNBC patients may be independent of the dysregulation in common tumor growth promoting pathways. It is likely that there may be hitherto unknown biomarkers that offer an enhanced understanding of the racial divide in TNBC outcomes.

Studies above suggest that the TNBC incidence and mortality rates are higher in AA compared to EA, even after adjusting for clinical and socioeconomic variables that might explain the differential outcome among the races (17). Thus, it is tempting to speculate that intrinsic biological factors might be responsible for the racially disparate burden of TNBC. In this lieu, it has been shown that TNBC patients of African descent harbor a higher prevalence of the basal-like-1 tumor phenotype which is characterized by enhanced proliferation and sensitivity to chemotherapy (17). AA women with TNBC tumors demonstrate a higher rate of invasion, distant metastasis (7.37% vs. 4.67%, p=0.05), angiogenesis and cell growth compared to their EA counterparts (26). Thus, proteins/biomarkers that are differentially expressed among the races and are involved in pathways associated with cell cycle regulation, epithelial-mesenchymal transition (EMT), and angiogenesis may hold the key to understanding therapeutically druggable targets to minimize the disparity gap. Indeed, selective inhibitors for specific pathways, which are in overdrive or underdrive, merit exploration to delineate a precise molecular mechanism of aggressiveness that is significantly associated with AA TNBC patients.

3.2. Tumor microenvironment in TNBC and racial disparity

Tumor cells do not live in isolation, rather they create a favorable niche known as tumor microenvironment (TME) to enhance the crosstalk with various other cells. Apart from tumor cells, TME is comprised of immune cells, fibroblasts, lymphocytes, signaling molecules, and tumor vasculature proteins. TME supports the growth, angiogenesis and metastasis of tumor cells (54). It has been reported that TME significantly influences the malignant behavior and is crucial for reprogramming the surrounding cells in TNBC. Myriad of available literature suggest that tumor infiltrating lymphocytes (TILs) are critical in regulating TNBC microenvironment. Elevated number of T regulatory cells (Tregs) in TME has been correlated with poor prognosis in many types of cancers including TNB (55, 56). Our unpublished data demonstrate a higher fraction of TILs in AA over EA TNBCs, suggesting that TME plays an essential role in racially disparate TNBC population. Moreover, vast majority of literature shed light on various TME related molecules (CXCL12, CXCR4, VEGF, Resistin, MCP1, MMP2, MMP-9, SOS1, PSPHL, uPA, IL6, RASSF1A, etc.) that are significantly up-regulated in AA over EA BC (57). These molecules along with their precise molecular action warrants further investigations to delineate the aggressive tumor biology associated with AA TNBC. Previously, various groups have reported that tougher extracellular matrix (ECM) was efficient in blocking the crosstalk between the cells. However, the recent data have suggested that stiffer the tumor stroma, more aggressive the breast cancer subtype is likely to be (55, 58). Thus, increased ECM rigidity might contribute in altering the mechano-signaling, tumor vasculature and pro-tumorigenic infiltration and thereby provide clues about highly invasive AA tumor phenotype over EA in TNBC. A detailed study characterizing the differential TME associated with AA and EA TNBC might give further insights into the TNBC racial disparity and could improve the prognosis of AA TNBC patients.

3.3. Differential gene signatures and pathways in racially distinct TNBC

Although various research groups have developed several small molecule inhibitors and antibodies against cell cycle pathway components, none to date have shown full clinical translation (27). It is imperative to understand the intrinsic tumor biology, heterogeneity and molecular basis of TNBC in AA women to improve their prognosis and identify novel therapeutic targets. Thus, investigating tumor suppressor proteins and oncogenes having differential expression profile between AA and EA TNBC patients represents an advantageous strategy, as explored in this section.

Various studies have demonstrated that the breast tumor microenvironment varies between AA and EA TNBC patients (25, 28, 29). Recently, published data from our laboratory, Ogden A et al., have demonstrated that nuclear (n) KIFC1 is a poor prognosis marker in AA TNBC compared to EA TNBC. In this multi-institutional study, we evaluated the expression of nKIFC1 in 163 AA and 144 EA TNBC patients using immunohistochemistry. Our data suggest that KIFC1 is an essential biomarker required for migration of AA TNBC tumor. High nKIFC1 weighed index (WI) was significantly related to worse overall survival (OS), progression-free survival (PFS) and high distant metastasis-free survival (DMFS) in AA but not EA TNBC (30). Using microarray analysis, Ademuyiwa et al., identified the top twenty upregulated genes in AA TNBC patients, including CRYBB2, FAM3A, CROCCL1, SCXB, PIF1, TRABD, TSPO, C6orf108, MIIP, C21orf70, TOP1MT, NACA2, PWP2, and BAX compared to EA TNBC patients. AA women have higher p53 gene mutations and lower PI3CA mutations over EA patients (25). Using laser capture microdissection, Martin et al., (28) analyzed genome-wide mRNA expression specific to tumor epithelium and stroma in AA and EA BC patients. Theirs and other related studies demonstrated upregulation of a panel of genes including CDKN2A, CCNA2, CCNB1, CCNE2, TMPO, AFMR, PSPHL, CXCL10, CXCL11, VEGF, syndecan-1, AURKB, CDCA5, CENPM, DDX11, and MK767 in AA TNBC patients compared to EA patients (28, 31, 32). It may be worthwhile to conduct validation studies to confirm the battery of genes or a “gene signature” that can stratify racially-distinct tumors and predict their risk of metastasis. Indeed, additional in vitro and in vivo experiments are warranted to reconcile the gene expression-based findings.

Even though TNBC incidence is higher in AA, several reports pinpoint significantly lower incidence of BRCA1 germline mutations in AA over EA TNBC, suggesting that other genetic mechanisms beyond germline BRCA1 mutation may explain the aggressive disease course in AA TNBC patients (33, 34). Genome-wide association studies (GWAS) showed that AA women have a higher frequency of risk variant at telomerase reverse transcriptase (TERT)-CLPTM1-like locus on chromosome 5p15 (odds ratio (OR)=1.25, p=1.1*10-9) (35). A genetic variant in the LOC643714 gene is associated with 23% increased risk for TNBC in AA but not in EA TNBC (OR=1.23, 95% confidence interval) (36). Gene expression profiles revealed higher expression of IGF1R, VEGF, and nuclear EZH2 in women with AA decent than in women with EA decent (17). Recent genomic and transcriptomic analyses revealed a loss of RB1 expression in ~20% TNBC patients. This RB1 loss is significantly related to higher sensitivity towards gamma irradiation, doxorubicin, and methotrexate therapy (37). Thus, RB1 status, and the molecular network upstream and downstream of RB1 in AA and EA TNBC separately are pivotal to gain insights into pathways that confer chemo resistance in racially diverse TNBC population. While LOXL2 and SNCG are novel prognostic markers studied in TNBC EMT, invasion and metastasis (38, 39), these markers merit an in-depth investigation in the context of racial disparity in TNBC to obtain essential clues about metastasis and poor survival in AA TNBC. A prostaglandin is producing the enzyme, Cox-2, is involved in cancer cell proliferation, anti-apoptosis, angiogenesis and invasion (40, 41). Dhakal et al., (41) found that Cox-2 expression is positively correlated with poor prognosis in TNBC than in non-TNBC patients. This study suggests a prognostic value of Cox-2 in TNBC, and thus, it is of significance to evaluate and validate its role within the racially diverse TNBC population.

3.4. Our Perspective: Looking racial disparity through a new lens

Using Next-Generation Sequencing (NGS) data from The Cancer Genome Atlas (TCGA), we analyzed several gene signatures in AA and EA TNBC. Surprisingly, we only found a few genes that showed a considerable difference in expression at the mRNA or protein level in AA and EA TNBC. These data indicated that the molecular basis of disparity might not be restricted to just the gene/protein expression based intrinsic tumor biology. It is well appreciated that protein diversity stemming due to alternative mRNA splicing or post-translational modifications (PTM) play vital roles in the modulation of cellular functions and protein-protein/protein-lipids crosstalks (42). PTMs are linked with a myriad of biological processes such as cell proliferation (43), differentiation (43), organismal development (44) and in the progression of human diseases including cancer (45). Advances in proteomics have critically fueled investigations into PTMs to reveal that these generate a complex combinatorial code regulating gene expression and protein functions, and whose deregulation has been documented in various types of cancers (46). PTMs at the molecular level amounts to altering the physical and chemical properties of proteins—in most cases reversibly—and in turn dictate their interaction with other cellular components such as protein, cell membranes, and DNA. Examples of PTMs, highly relevant in the context of cancer, include phosphorylation, acetylation, lipidation, sumoylation, methylation, and glycosylation which rewire the oncogenic signaling pathways in response to various stimuli surprisingly including tumor microenvironment, nutrient status, and hypoxia (47). The current status on the role of PTMs states that the pattern of post-translational modifications is a better predictive biomarker than the changes in total protein level and gives an additional layer of complexity by fine-tuning downstream signaling events (48). Thus, it is highly tempting to speculate that mapping of the PTMs patterns with the genomic and proteomic profile is likely to serve as a next-generation biomarker for improved prognosis of the disease, simultaneously providing a protein network framework amenable for therapeutic targeting in a spatiotemporal fashion.

Befittingly, a tantalizing possibility that may explain the TNBC disparity beyond differences at the gene and protein expression level is a differential profile of PTMs. Recent data by Golavilli PN et al., have shown that in TNBC, AMP-activated protein kinases (AMPK) activates glycogen synthase kinase 3 beta (GSK3β) and Sirtuin 1(SIRT1) by inhibiting phosphorylation at Ser9 and Ser47, respectively. This activation of GSK3β and SIRT1, in turn, inhibit the upregulation of metadherin (MTDH) and suppresses TNBC cell proliferation (49). Hanigan TW et al., have evidenced that c-Jun N-terminal kinase (JNK) mediated histone deacetylase 3 (HDAC3) phosphorylation in TNBC cells is essential for HDAC inhibitor binding and selectivity (50). These studies collectively suggest a non-trivial role of PTMs in TNBC. However, to the best of our knowledge, there is no study showing that PTMs might be one of the factors responsible for the underlying TNBC racial disparity. Our unpublished data suggest that PTMs (phosphorylation, acetylation, and sumoylation) may account for the disproportionately higher burden of TNBC in AA population and concomitantly may shed light on the aggressive nature of AA TNBC compared with EAs. This space of post-translational regulation is an uncharted terrain and presents an attractive avenue that merits extensive and intensive exploration to address racial disparity in TNBC.

Indeed, the cumulative effect of multiple genes and their underlying molecular pathways define the tumor phenotype. However, to date, there are very limited therapeutic options, mainly because of the paucity of in-depth knowledge about the intrinsic tumor biology of AA and EA TNBC. Identifying enrichment of biological networks in the tumor epithelium and tumor stroma might help to stratify the AA and EA TNBC patients and improve treatment regimen. Gene expression profiles suggested that tumor angiogenesis and chemotaxis pathway are functionally different between AA and EA BC patients (51-53). These pathways and underlying genes associated with these need to be evaluated in detail to understand the racial disparity in TNBC. We have performed a gene ontology (GO) analysis to trace out the genes and gene pathways that might be differentially regulated in AA and EA TNBC. Our analysis revealed the top ten gene pathways that are significantly up and down-regulated in AA and EA TNBC. The top five pathways that are up-regulated in AA TNBC include, i. Hematopoietic or lymphoid organ development (GO:0048534, p=0.0004), ii. Leukocyte differentiation (GO:0002521, p=0.00046), iii. Hemopoiesis (GO:0030097, p=0.0005), iv. Immune effector process (GO:0002252, p=0.00060), v. Lymphocyte differentiation (GO:0030098, p=0.00066). The top five pathways that are downregulated in AA TNBC over EA are i. Post-translational protein modification (GO:0043687, p=0.000494), ii. Homophilic cell adhesion (GO:0007156, p=0.00089), iii. Glycosylation (GO:0070085, p=0.00192), iv. Protein glycosylation (GO:0006486, p=0.0020), v. Macromolecule Glycosylation (GO:0043413, p=0.0020). The gene signatures associated with these up and down-regulated pathways must be studied to evaluate the precise molecular mechanism of action that can improve the trajectory of AA TNBC tumor biology and may give pointers on the aggressive disease course in AA TNBC over EA. Differentially expressed genes in AA TNBC can be found in Table 1. Future in-depth studies would be decisive in addressing the precise molecular regulation associated with the genes and pathways mentioned above to delineate the disparate tumor burden in AA TNBC. The landscape of molecular players that are differentially regulated at the transcriptional, post-transcriptional, translational or post-translational level may be the “next thing” to investigate to deconvolve the complexities surrounding TNBC racial disparity and might offer mechanistic cues that can directly translate to improve the prognosis and survival of AA TNBC patients.

Table 1. Significantly up and down-regulated genes in AA compared to EA TNBC analyzed using TCGA breast cancer dataset, p value less than 0.01 and log2fold change greater than 1.0 (upregulated) and less than -1.0. (downregulated)
Gene symbolGene nameGene symbolGene name
KLK14kallikrein-related peptidase 14STON1-GTF2A1LSTON1-GTF2A1L readthrough
RETNresistinFAM83Afamily with sequence similarity 83 member A
TREML4triggering receptor expressed on myeloid cells like 4NEFHneurofilament heavy polypeptide
NACA2nascent polypeptide-associated complex alpha subunit 2DEFB1defensin beta 1
UPK3Buroplakin 3BGNG4G protein subunit gamma 4
KRT8P41keratin 8 pseudogene 41MUCL1mucin like 1
HAPLN1hyaluronan and proteoglycan link protein 1NPTX2neuronal pentraxin 2
TCTE1t-complex-associated-testis-expressed 1ADGRL3adhesion G protein-coupled receptor L3
JSRP1junctional sarcoplasmic reticulum protein 1ENDOUendonuclease, poly (U) specific
CCL3L1C-C motif chemokine ligand 3 like 1GPAT2glycerol-3-phosphate acyltransferase 2, mitochondrial
KLK10kallikrein-related peptidase 10CAMPcathelicidin antimicrobial peptide
MYEOVmyeloma overexpressedFAIM2Fas apoptotic inhibitory molecule 2
PPP1R14Aprotein phosphatase 1 regulatory inhibitor subunit 14AEYA1EYA transcriptional coactivator and phosphatase 1
ACOXLacyl-CoA oxidase-likeSYTL5synaptotagmin like 5
LEFTY1left-right determination factor 1CYP2B7Pcytochrome P450 family 2 subfamily B member 7, pseudogene
SYCE1synaptonemal complex central element protein 1FGL1fibrinogen like 1
CCDC154coiled-coil domain containing 154EPGNepithelial mitogen
LAIR2leukocyte-associated immunoglobulin-like receptor 2ST8SIA2ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2
CSDC2cold shock domain containing C2FREM2FRAS1 related extracellular matrix protein 2
DHDHdihydrodiol dehydrogenaseAKR1B15aldo-keto reductase family 1 member B15
AZU1azurocidin 1FABP6fatty acid binding protein 6
FGF17fibroblast growth factor 17IGF2insulin like growth factor 2
WNT6Wnt family member 6PRLRprolactin receptor
BMP2bone morphogenetic protein 2TUBA3Dtubulin alpha 3d
FBXO2F-box protein 2FIGNfidgetin, microtubule severing factor
MEF2Bmyocyte enhancer factor 2BNANA
C1QL2complement C1q like 2CLCA2chloride channel accessory 2
MZB1marginal zone B and B1 cell specific proteinARandrogen receptor
LRRC14Bleucine rich repeat containing 14BRERGLRERG like
TSGA10IPtestis specific 10 interacting proteinPHEXphosphate regulating endopeptidase homolog, X-linked
PRKYprotein kinase, Y-linked, pseudogeneHTR1B5-hydroxytryptamine receptor 1B
DCST2DC-STAMP domain containing 2NCAM2neural cell adhesion molecule 2
CLIC3chloride intracellular channel 3NLGN1neuroligin 1
ART3ADP-ribosyltransferase 3SLC7A2solute carrier family 7 member 2
RNF112ring finger protein 112HOXA11homeobox A11
MAPK15mitogen-activated protein kinase 15BEX1brain expressed X-linked 1
AARDalanine and arginine rich domain containing proteinENPP3ectonucleotide pyrophosphatase/phosphodiesterase 3
FOXF2forkhead box F2FUT6fucosyltransferase 6
ACTN3actinin alpha 3 (gene/pseudogene)NANA
CDHR1cadherin related family member 1ATP2B2ATPase plasma membrane Ca2+transporting 2
SP7Sp7 transcription factorCLLU1OSchronic lymphocytic leukemia up-regulated 1 opposite strand
KLK11kallikrein related peptidase 11DCXdoublecortin
FOXH1forkhead box H1NRG3neuregulin 3
NKX2-3NK2 homeobox 3TENM2teneurin transmembrane protein 2
FAM222A-AS1FAM222A antisense RNA 1NRXN3neurexin 3
KRT3keratin 3TNRtenascin R
P2RX1purinergic receptor P2X 1NKAIN1Na+/K+transporting ATPase interacting 1
TSPAN32tetraspanin 32CLGNcalmegin
TUBB8tubulin beta 8 class VIIICYP4F22cytochrome P450 family 4 subfamily F member 22
WNT2BWnt family member 2BTMEM246transmembrane protein 246
CAMKVCaM kinase like vesicle associatedRIMKLAribosomal modification protein rimK like family member A
CALML6calmodulin like 6PKIBprotein kinase (cAMP-dependent, catalytic) inhibitor beta
LGR6leucine rich repeat containing G protein-coupled receptor 6DSG1desmoglein 1
KISS1KiSS-1 metastasis-suppressorZMAT4zinc finger matrin-type 4
FOXQ1forkhead box Q1TRPA1transient receptor potential cation channel subfamily A member 1
CNBD2cyclic nucleotide binding domain containing 2SH3GL2SH3 domain containing GRB2 like 2, endophilin A1
ICAM5intercellular adhesion molecule 5PCP4Purkinje cell protein 4
KRT38keratin 38STC1stanniocalcin 1
TMPRSS5transmembrane protease, serine 5HCRTR2hypocretin receptor 2
SLC22A20solute carrier family 22 member 20ELAVL3ELAV like RNA binding protein 3
RADILRap associating with DIL domainAFF3AF4/FMR2 family member 3
FOLR3folate receptor 3CA3carbonic anhydrase 3

4. Conclusion

A multitude of genes and their underlying molecular pathways define the tumor phenotype. Within the TNBC subtype, tumor phenotype is distinct among the women from African decent vs. the one with European descent, and thus AA women exhibit poor survival and prognosis. To date, there are very limited therapeutic options, mainly because of the intrinsic tumor biology of AA and EA TNBC is not clear. Thus, a landscape of molecular players that are differentially regulated at transcription, post-transcription, translation or post-translation level may be beneficial to investigate the TNBC racial disparity and might help to improve the prognosis and survival of AA TNBC patients. Identifying enrichment of biological networks in the tumor epithelium and tumor stroma might help to stratify the AA and EA TNBC patients and improve treatment regimen. Gene expression profiles suggested that tumor angiogenesis and chemotaxis pathway are functionally different between AA and EA TNBC patients. These pathways and underlying genes associated with these need to be evaluated in detail to understand the racial disparity in TNBC. Thus, there is an unmet need to determine the molecular players and their underlying mechanism of action to improve the AA TNBC prognosis and survival.

5. Acknowledgement

The authors are thankful to Ms. Nikita Wright for the constructive criticisms and thorough analytical reading of the manuscript.


    1. J. H. Silber, P. R. Rosenbaum, A. S. Clark, B. J. Giantonio, R. N. Ross, Y. Teng, M. Wang, B. A. Niknam, J. M. Ludwig, W. Wang, O. Even-Shoshan and K. R. Fox: Characteristics associated with differences in survival among black and white women with breast cancer. JAMA, 310(4), 389-397 (2013)

    2. B. D. Lehmann and J. A. Pietenpol: Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol, 232(2), 142-50 (2014)

    3. P. Boyle: Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol, 23 Suppl 6, vi7-12 (2012)

    4. J. M. Pacheco, F. Gao, C. Bumb, M. J. Ellis and C. X. Ma: Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat, 138(1), 281-9 (2013)

    5. K. R. Bauer, M. Brown, R. D. Cress, C. A. Parise and V. Caggiano: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 109(9), 1721-8 (2007)

    6. F. Kassam, K. Enright, R. Dent, G. Dranitsaris, J. Myers, C. Flynn, M. Fralick, R. Kumar and M. Clemons: Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design. Clinical Breast Cancer, 9(1), 29-33 (2009)

    7. O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz and N. Harbeck: Triple-negative breast cancer—current status and future directions. Annals of Oncology, 20(12), 1913-1927 (2009)

    8. F. Poggio, M. Bruzzone, M. Ceppi, B. Conte, S. Martel, C. Maurer, M. Tagliamento, G. Viglietti, L. Del Mastro, E. de Azambuja and M. Lambertini: Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open, 3(4), e000361 (2018)

    9. J. J. J. Geenen, S. C. Linn, J. H. Beijnen and J. H. M. Schellens: PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clin Pharmacokinet, 57(4), 427-437 (2018)

    10. B. Corkery, J. Crown, M. Clynes and N. O’Donovan: Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Annals of Oncology, 20(5), 862-867 (2009)

    11. A. A. Changavi, A. Shashikala and A. S. Ramji: Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas. Journal of Laboratory Physicians, 7(2), 79-83 (2015)

    12. E. Caldas-Lopes, L. Cerchietti, J. H. Ahn, C. C. Clement, A. I. Robles, A. Rodina, K. Moulick, T. Taldone, A. Gozman, Y. Guo, N. Wu, E. de Stanchina, J. White, S. S. Gross, Y. Ma, L. Varticovski, A. Melnick and G. Chiosis: Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America, 106(20), 8368-8373 (2009)

    13. R. S. Finn, J. Dering, C. Ginther, C. A. Wilson, P. Glaspy, N. Tchekmedyian and D. J. Slamon: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/”triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment, 105(3), 319-326 (2007)

    14. B. K. Linderholm, H. Hellborg, U. Johansson, G. Elmberger, L. Skoog, J. Lehtiö and R. Lewensohn: Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Annals of Oncology, 20(10), 1639-1646 (2009)

    15. S. F. Dent: The role of VEGF in triple-negative breast cancer: where do we go from here? Annals of Oncology, 20(10), 1615-1617 (2009)

    16. J. A. Sparano, L. J. Goldestin, B. H. Childs, S. Shak, S. Badve, F. L. Baehner, N. E. Davidson, G. W. S. Jr. and R. Gray: Genotypic characterization of phenotypically defined triple-negative breast cancer. Journal of Clinical Oncology, 27(15_suppl), 500-500 (2009)

    17. E. C. Dietze, C. Sistrunk, G. Miranda-Carboni, R. O’Regan and V. L. Seewaldt: Triple-negative breast cancer in African-American women: disparities versus biology. Nature reviews. Cancer, 15(4), 248-254 (2015)

    18. C. Tammemagi, D. Nerenz, C. Neslund-Dudas, C. Feldkamp and D. Nathanson: Comorbidity and survival disparities among black and white patients with breast cancer. JAMA, 294(14), 1765-1772 (2005)

    19. M. J. Lund, K. F. Trivers, P. L. Porter, R. J. Coates, B. Leyland-Jones, O. W. Brawley, E. W. Flagg, R. M. O’Regan, S. G. A. Gabram and J. W. Eley: Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Research and Treatment, 113(2), 357-370 (2009)

    20. L. A. Carey, C. M. Perou, C. A. Livasy, L. G. Dressler, D. Cowan, K. Conway, K. G., M. A. Troester, C. K. Tse, S. Edmiston, S. L. Deming, J. Geradts, M. C. Cheang, T. O. Nielsen, P. G. Moorman, H. S. Earp and R. C. Millikan: Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA, 295(21), 2492-2502 (2006)

    21. J. C. Sachdev, S. Ahmed, M. M. Mirza, A. Farooq, L. Kronish and M. Jahanzeb: Does Race Affect Outcomes in Triple Negative Breast Cancer? Breast Cancer : Basic and Clinical Research, 4, 23-33 (2010)

    22. S. Dawood, K. Broglio, S.-W. Kau, M. C. Green, S. H. Giordano, F. Meric-Bernstam, T. A. Buchholz, C. Albarracin, W. T. Yang, B. T. J. Hennessy, G. N. Hortobagyi and A. M. Gonzalez-Angulo: Triple Receptor–Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. Journal of Clinical Oncology, 27(2), 220-226 (2009)

    23. K. M. O’Brien, S. R. Cole, C.-K. Tse, C. M. Perou, L. A. Carey, W. D. Foulkes, L. G. Dressler, J. Geradts and R. C. Millikan: Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 16(24), 6100-6110 (2010)

    24. J. A. Sparano, M. Wang, F. Zhao, V. Stearns, S. Martino, J. A. Ligibel, E. A. Perez, T. Saphner, A. C. Wolff, G. W. Sledge, W. C. Wood and N. E. Davidson: Race and Hormone Receptor–Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial. JNCI Journal of the National Cancer Institute, 104(5), 406-414 (2012)

    25. F. O. Ademuyiwa, Y. Tao, J. Luo, K. Weilbaecher and C. X. Ma: Differences in the mutational landscape of triple negative breast cancer in African Americans and Caucasians. Breast cancer research and treatment, 161(3), 491-499 (2017)

    26. M. S. Hamid, R. Shameem, A. Pudusseri, R. Graham, D. Shani and K. M. Sullivan: Racial/ethnic disparities in clinicopathologic features and treatment modalities of triple-negative breast cancer in black premenopausal women. Journal of Clinical Oncology, 32(26_suppl), 58-58 (2014)

    27. F. P. Parvin, J. E. Matthew and M. Cynthia: Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy. International Journal of Breast Cancer, 2012 (2012)

    28. D. N. Martin, B. J. Boersma, M. Yi, M. Reimers, T. M. Howe, H. G. Yfantis, Y. C. Tsai, E. H. Williams, D. H. Lee, R. M. Stephens, A. M. Weissman and S. Ambs: Differences in the Tumor Microenvironment between African-American and European-American Breast Cancer Patients. PLoS ONE, 4(2), e4531 (2009)

    29. S. Kalla Singh, Q. W. Tan, C. Brito, M. De León and D. De León: Insulin-like growth factors I and II receptors in the Breast Cancer Survival Disparity among African-American Women. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 20(3), 245-254 (2010)

    30. A. Ogden, C. Garlapati, X. Bill) Li, R. C. Turaga, G. Oprea, N. Wright, S. Bhattarai, K. Mittal, C. Sonmez Wetherilt, U. Krishnamurti, M. Reid, M. Jones, M. Gupta, R. Osan, S. Pattni, A. Riaz, S. Klimov, A. Rao, G. Cantuaria and R. Aneja: Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. (2017)

    31. S. S. Kalla, Q. W. Tan, C. Brito, M. De León and D. De León: Differential Insulin-like Growth Factor II (IGF-II) Expression: A Potential Role for Breast Cancer Survival Disparity. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 20(2), 162-170 (2010)

    32. R. Lindner, C. Sullivan, O. Offor, K. Lezon-Geyda, K. Halligan, N. Fischbach, M. Shah, V. Bossuyt, V. Schulz, D. P. Tuck and L. N. Harris: Molecular Phenotypes in Triple Negative Breast Cancer from African American Patients Suggest Targets for Therapy. PLoS ONE, 8(11), e71915 (2013)

    33. R. Nanda, L. Schumm, S. Cummings, J. D. Fackenthal, L. Sveen, F. Ademuyiwa, M. Cobleigh, L. Esserman, N. M. Lindor, S. L. Neuhausen and O. I. Olopade: Genetic testing in an ethnically diverse cohort of high-risk women: A comparative analysis of brca1 and brca2 mutations in american families of european and african ancestry. JAMA, 294(15), 1925-1933 (2005)

    34. O. I. Olopade, J. D. Fackenthal, G. Dunston, M. A. Tainsky, F. Collins and C. Whitfield-Broome: Breast cancer genetics in African Americans. Cancer, 97(1), 236-245 (2003)

    35. C. A. Haiman, G. K. Chen, C. M. Vachon, F. Canzian, A. Dunning, R. C. Millikan, X. Wang, F. Ademuyiwa, S. Ahmed, C. B. Ambrosone, L. Baglietto, R. Balleine, E. V. Bandera, M. W. Beckmann, C. D. Berg, L. Bernstein, C. Blomqvist, W. J. Blot, H. Brauch, J. E. Buring, L. A. Carey, J. E. Carpenter, J. Chang-Claude, S. J. Chanock, D. I. Chasman, C. L. Clarke, A. Cox, S. S. Cross, S. L. Deming, R. B. Diasio, A. M. Dimopoulos, W. R. Driver, T. Dünnebier, L. Durcan, D. Eccles, C. K. Edlund, A. B. Ekici, P. A. Fasching, H. S. Feigelson, D. Flesch-Janys, F. Fostira, A. Försti, G. Fountzilas, S. M. Gerty, I. The Gene Environment, C. Breast Cancer in Germany, G. G. Giles, A. K. Godwin, P. Goodfellow, N. Graham, D. Greco, U. Hamann, S. E. Hankinson, A. Hartmann, R. Hein, J. Heinz, A. Holbrook, R. N. Hoover, J. J. Hu, D. J. Hunter, S. A. Ingles, A. Irwanto, J. Ivanovich, E. M. John, N. Johnson, A. Jukkola-Vuorinen, R. Kaaks, Y.-D. Ko, L. N. Kolonel, I. Konstantopoulou, V.-M. Kosma, S. Kulkarni, D. Lambrechts, A. M. Lee, L. Le Marchand, T. Lesnick, J. Liu, S. Lindstrom, A. Mannermaa, S. Margolin, N. G. Martin, P. Miron, G. W. Montgomery, H. Nevanlinna, S. Nickels, S. Nyante, C. Olswold, J. Palmer, H. Pathak, D. Pectasides, C. M. Perou, J. Peto, P. D. P. Pharoah, L. C. Pooler, M. F. Press, K. Pylkäs, T. R. Rebbeck, J. L. Rodriguez-Gil, L. Rosenberg, E. Ross, T. Rüdiger, I. d. S. Silva, E. Sawyer, M. K. Schmidt, R. Schulz-Wendtland, F. Schumacher, G. Severi, X. Sheng, L. B. Signorello, H.-P. Sinn, K. N. Stevens, M. C. Southey, W. J. Tapper, I. Tomlinson, F. B. L. Hogervorst, E. Wauters, J. Weaver, H. Wildiers, R. Winqvist, D. Van Den Berg, P. Wan, L. Y. Xia, D. Yannoukakos, W. Zheng, R. G. Ziegler, A. Siddiq, S. L. Slager, D. O. Stram, D. Easton, P. Kraft, B. E. Henderson and F. J. Couch: A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nature Genetics, 43(12), 1210-1214 (2011)

    36. E. A. Ruiz-Narváez, L. Rosenberg, Y. C. Cozier, L. A. Cupples, L. L. Adams-Campbell and J. R. Palmer: Polymorphisms in the TOX3/LOC643714 locus and risk of breast cancer in African-American women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 19(5), 1320-1327 (2010)

    37. T. J. W. Robinson, J. C. Liu, F. Vizeacoumar, T. Sun, N. Maclean, S. E. Egan, A. D. Schimmer, A. Datti and E. Zacksenhaus: RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs. PLoS ONE, 8(11), e78641 (2013)

    38. S. G. Ahn, S. M. Dong, A. Oshima, W. H. Kim, H. M. Lee, S. A. Lee, S.-h. Kwon, J.-h. Lee, J. M. Lee, J. Jeong, H.-D. Lee and J. E. Green: LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Research and Treatment, 141(1), 89-99 (2013)

    39. G. Moreno-Bueno, F. Salvador, A. Martín, A. Floristán, E. P. Cuevas, V. Santos, A. Montes, S. Morales, M. A. Castilla, A. Rojo-Sebastián, A. Martínez, D. Hardisson, K. Csiszar, F. Portillo, H. Peinado, J. Palacios and A. Cano: Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Molecular Medicine, 3(9), 528-544 (2011)

    40. L. Zhou, K. Li, Y. Luo, L. Tian, M. Wang, C. Li and Q. Huang: Novel prognostic markers for patients with triple-negative breast cancer. Human Pathology, 44(10), 2180-2187 (2013)

    41. H. Prasad Dhakal, B. Naume, M. Synnestvedt, E. Borgen, R. Kaaresen, E. Schlichting, G. Wiedswang, A. Bassarova, R. Holm, K.-E. Giercksky and J. M Nesland: Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact. (2012)

    42. C. T. Walsh, S. Garneau-Tsodikova and G. J. Gatto: Protein Posttranslational Modifications: The Chemistry of Proteome Diversifications. Angewandte Chemie International Edition, 44(45), 7342-7372 (2005)

    43. A. P. Chandrasekaran, B. Suresh, H. Kim, K.-S. Kim and S. Ramakrishna: Concise Review: Fate Determination of Stem Cells by Deubiquitinating Enzymes. STEM CELLS, 35(1), 9-16 (2017)

    44. S.-i. Okamoto and S. A. Lipton: S-Nitrosylation in neurogenesis and neuronal development. Biochimica et biophysica acta, 1850(8), 1588-1593 (2015)

    45. A. Eisenberg-Lerner, A. Ciechanover and Y. Merbl: Post-translational modification profiling – A novel tool for mapping the protein modification landscape in cancer. Experimental Biology and Medicine, 241(14), 1475-1482 (2016)

    46. K. W. Barber and J. Rinehart: The ABCs of PTMs. Nat Chem Biol, 14(3), 188-192 (2018)

    47. M. V. Dwek, H. A. Ross and A. J. Leathem: Proteome and glycosylation mapping identifies post-translational modifications associated with aggressive breast cancer. Proteomics, 1(6), 756-62 (2001)

    48. A. Martín-Bernabé, C. Balcells, J. Tarragó-Celada, C. Foguet, S. Bourgoin-Voillard, M. Seve and M. Cascante: The importance of post-translational modifications in systems biology approaches to identify therapeutic targets in cancer metabolism. Current Opinion in Systems Biology, 3, 161-169 (2017)

    49. P. N. Gollavilli, A. K. Kanugula, R. Koyyada, S. Karnewar, P. K. Neeli and S. Kotamraju: AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation. The FEBS Journal, 282(20), 3971-3985 (2015)

    50. T. W. Hanigan, S. M. Aboukhatwa, T. Y. Taha, J. Frasor and P. A. Petukhov: Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity. Cell Chemical Biology, 24(11), 1356-1367.e8 (2017)

    51. N. Weidner, J. P. Semple, W. R. Welch and J. Folkman: Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma. New England Journal of Medicine, 324(1), 1-8 (1991)

    52. E. Y. Lin and J. W. Pollard: Role of infiltrated leucocytes in tumour growth and spread. British Journal of Cancer, 90(11), 2053-2058 (2004)

    53. L. Bingle, N. J. Brown and C. E. Lewis: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. The Journal of Pathology, 196(3), 254-265 (2002)

    54. F. R. Balkwill, M. Capasso and T. Hagemann: The tumor microenvironment at a glance. J Cell Sci, 125(23), 5591-5596 (2012)

    55. T. Yu and G. Di: Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Chinese J Cancer Res 29(3), 237-252 (2017)

    56. L. de la Cruz-Merino, A. Barco-Sánchez, F. Henao Carrasco, E. Nogales Fernández, A. Vallejo Benítez, J. Brugal Molina, A. Martínez Peinado, A. Grueso López, M. Ruiz Borrego, M. Codes Manuel de Villena, V. Sánchez-Margalet, A. Nieto-García, E. Alba Conejo, N. Casares Lagar and J. Ibáñez Martínez: New insights into the role of the immune microenvironment in breast carcinoma. Clinical & developmental immunology, 2013, 785317-785317 (2013)

    57. S. K. Deshmukh, S. K. Srivastava, N. Tyagi, A. Ahmad, A. P. Singh, A. A. L. Ghadhban, D. L. Dyess, J. E. Carter, K. Dugger and S. Singh: Emerging evidence for the role of differential tumor microenvironment in breast cancer racial disparity: a closer look at the surroundings. Carcinogenesis, 38(8), 757-765 (2017)

    58. S. Kaushik, M. W. Pickup and V. M. Weaver: From transformation to metastasis: deconstructing the extracellular matrix in breast cancer. Cancer metastasis reviews, 35(4), 655-667 (2016)

Share and Cite
Chakravarthy Garlapati, Shriya Joshi, Bikram Sahoo, Shobhna Kapoor, Ritu Aneja. The persisting puzzle of racial disparity in triple negative breast cancer: looking through a new lens. Frontiers in Bioscience-Scholar. 2019. 11(1); 75-88.